<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376503</url>
  </required_header>
  <id_info>
    <org_study_id>NNG04</org_study_id>
    <nct_id>NCT03376503</nct_id>
  </id_info>
  <brief_title>Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Study Comparing Pharmacokinetic (PK) and Pharmacodynamic (PD) Parameters of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Chemotherapy-induced Neutropenia in Breast-cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanogen Pharmaceutical Biotechnology Joint Stock Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanogen Pharmaceutical Biotechnology Joint Stock Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will
      be enrolled in this study. Eligible patients receive single SC injection of pegcyte or
      neulastim 24 hours after administration of chemotherapy (Doxorubicin and Cyclophosphamide) in
      the first cycle (14 days each cycle). Blood samples are collected to determine the serum
      concentration of investigational drugs at specific time points in the first cycle. Absolute
      neutrophil count, CD34+ count, Cmax (maximum serum concentration), AUC0-t (area under the
      curve of the plasma concentration time) and Tmax (time required to reach Cmax) will be
      calculated from the serum concentration profile
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2016</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">October 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from time 0 to the last time point (AUC0-t) for serum Pegfilgrastim (PEG-GCSF)</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
    <description>(AUC0-t)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL) for serum Pegfilgrastim</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) for serum Pegfilgrastim</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T½) for serum Pegfilgrastim (PEG-GCSF)</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC0-inf) of Pegfilgrastim</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) for serum Pegfilgrastim</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz) for serum Pegfilgrastim</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change in CD34+ count</measure>
    <time_frame>day 2 (0h), day 5 (72h), day 7 (120h), and day 8 (144h) of the first cycle.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve above baseline of ANC [ANC_AUC(0-tlast)]</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum change from baseline for ANC in days (ANC_Tmax)</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in absolute neutrophil count from time 0 to the last time point ANC AUC0-t</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in absolute neutrophil count (ANC); ANC_Cmax</measure>
    <time_frame>day 2 (0h, 3h, 6h, 12±4h), day 3 (24h), day 4 (48h), day 5 (72h), day 7 (120h), day 8 (144h), day 9 (168h), day 11 (216h), and day 14 (288h) of the first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>cycle 1 from day 2 to day 14</time_frame>
    <description>Including changes in vitals and laboratory investigations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pegcyte (Nanogen pegfilgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegcyte 6 mg in the first cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulastim (Roche pegfilgrastim)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neulastim 6 mg in the first cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>PK,PD and safety assessment</description>
    <arm_group_label>Pegcyte (Nanogen pegfilgrastim)</arm_group_label>
    <arm_group_label>Neulastim (Roche pegfilgrastim)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged between 18 - 65 years.

          -  Patients with histological confirmed primary invasive breast cancer; stage I, II or
             III.

          -  Patients had no prior chemotherapy treatments.

          -  Patients scheduled to undergo myelosuppressive Doxorubicin and Cyclophosphamide
             chemotherapy for 04 cycles, and Paclitaxel chemotherapy for the next 04 cycles;
             patients were available for 14 days of each cycle for the first 03 chemotherapy
             cycles.

          -  Patients with baseline ANC ≥ 1.5 x 109/L, PLT ≥ 100 x 109/L, HgB ≥ 9 g/dL, WBC ≥
             3,000/mL and albumin ≥ 3.0 g/dL.

          -  Performance status as per ECOG (Eastern Cooperative Oncology Group) score 0, 1 or 2.

          -  Willing to give written and signed informed consent

        Exclusion Criteria:

          -  Patients with prior exposure of G-CSF or GM-CSF or its pegylated products in clinical
             development less than 6 months prior to randomization.

          -  Myelotoxic concomitant treatment such as chloramphenicol, methotrexate,
             immunomodulating agents, interferons during 10 days before randomization.

          -  Received systemic antibiotic treatment within 72 hours of chemotherapy.

          -  Chronic use of corticosteroids, prior bone marrow or stem cell transplant.

          -  Patients who had an immediate/ concurrent exposure to radiotherapy or surgery (within
             4 weeks).

          -  Severe medical disease: cardiovascular, hepatic, renal, pulmonary…

          -  Known cases of hematological disease (sickle cell anemia, AML…)

          -  History of HIV positive, active hepatitis.

          -  Pregnant and lactating women or patients planning to become pregnant.

          -  Known allergic reactions to study medications.

          -  Positive to anti-pegfilgrastim antibody test.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vietnam National Cancer Institute (Hospital K)</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

